Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia

Golden Biotechnology

Status

Completed

Conditions

Benign Prostatic Hyperplasia

Treatments

Dietary Supplement: Umooze

Dietary Supplement: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT02313233

IRC01110908

Details and patient eligibility

About

To evaluate the improvement in symptoms of Benign Prostatic Hyperplasia (BPH) according to the Prostate Symptom Score (IPSS) and Quality- of- Life (QoL) index after add- on therapy of Umooze twice daily administration for 56 days in patients with BPH.

Full description

The study product, Umooze, contain Astragalus radix extracts and Soy extracts as the combination of 960:40 in one 500 mg tablet. Umooze is sold in the market as food. The objective of this study is to evaluate the benefit of Umooze as add- on therapy in BPH, by evaluation the improvement in symptoms of BPH assessed according to the International Prostate Symptom Score (IPSS) and Quality- of- Life (QoL) index after add- on therapy of Umooze in patients with BPH. The IPSS is a validated 7-item urinary symptom severity scale.

A randomized, two-regimen, placebo-controlled, parallel- design is used in this study in which each subject will receive Umooze or placebo. The add- on study product will be administered twice daily for 56 days. Benefit will be evaluated at baseline and subsequently on the study day 28, 42, and 56, such as IPSS index, QoL index, Qmax, PVR, prostate volume and Prostate-specific antigen(PSA).

Enrollment

41 patients

Sex

Male

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males aged >=40 years old
Screened by inquiry and diagnosed as BPH based on the result of a digital rectal examination (DRE) or transrectal ultrasonography (TRUS)
Prostate volume >= 20 cm3
Has complained of voiding symptoms related to BPH
Has an IPSS >= 13 or an UFR measure of Qmax <= 15 ml/sec together with a voided volume >= 150 ml.
Serum PSA < 6.5 ng/ml
Has been treated with medication for BPH
Informed consent form signed.

Exclusion criteria

Sensitivity to study product
Had received prostatic surgery for BPH during the past 24 weeks
Hard nodule found by DRE
Ongoing neurogenic bladder, urinary tract infection, bladder stone, urethral stricture, bladder cancer, prostate cancer, severe liver dysfunction, severe renal dysfunction or severe cardiovascular disease.
Patient has clinically significant physical disability or abnormal findings on physical examination or laboratory testing judged by the investigator or co- investigator.
Participation of any clinical investigation during the last 30 days.
Individuals are judged by the investigators or co- investigator to be undesirable as subjects.